Literature DB >> 1868416

Mortality in a cohort of patients with schizophrenia: a record linkage study.

S C Newman1, R C Bland.   

Abstract

A retrospective study of mortality was conducted in which 3,623 patients with schizophrenia receiving treatment in Alberta between 1976 and 1985 were followed to the end of 1985. Vital status was determined by record linkage to the Statistics Canada Mortality Data Base. There were 301 deaths in the cohort, 97 of which were due to suicide. For all causes of death combined, the risk of mortality was approximately double that of the Alberta population; for suicide, risk was increased by a factor of 20. Mortality from circulatory, respiratory, digestive and genitourinary diseases was also greater than expected. It is estimated that those who suffer from schizophrenia have a life expectancy which is approximately 20% shorter than that of the general population. This study confirms earlier research demonstrating an increased risk of mortality associated with schizophrenia and extends those findings to specific causes of death.

Entities:  

Mesh:

Year:  1991        PMID: 1868416     DOI: 10.1177/070674379103600401

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  62 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Modelling the treated course of schizophrenia: development of a discrete event simulation model.

Authors:  Bart Heeg; Erik Buskens; Martin Knapp; Gerda van Aalst; Pieter J T Dries; Lieuwe de Haan; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Authors:  Gerd Laux; Bart Heeg; Ben A van Hout; Angelika Mehnert
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Cardiovascular risk assessment and management in mental health clients: whose role is it anyway?

Authors:  Amanda J Wheeler; Jeff Harrison; Priya Mohini; Jeshika Nardan; Amy Tsai; Eve Tsai
Journal:  Community Ment Health J       Date:  2009-08-18

6.  The cost-effectiveness of clozapine: a survey of the literature.

Authors:  S Morris; T Hogan; A McGuire
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

7.  Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?

Authors:  Maju Mathew Koola; Jeffrey K Raines; Robert G Hamilton; Robert P McMahon
Journal:  Curr Psychiatr       Date:  2016-04-25

8.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

9.  Cigarette smoking and mortality risk in people with schizophrenia.

Authors:  Deanna L Kelly; Robert P McMahon; Heidi J Wehring; Fang Liu; Kristen M Mackowick; Douglas L Boggs; Kimberly R Warren; Stephanie Feldman; Joo-Cheol Shim; Raymond C Love; Lisa Dixon
Journal:  Schizophr Bull       Date:  2009-12-17       Impact factor: 9.306

Review 10.  Lipid effects of psychiatric medications.

Authors:  Junzo Watanabe; Yutaro Suzuki; Toshiyuki Someya
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.